1. C-terminal BRE overexpression in 11q23-rearranged and t(8;16) acute myeloid leukemia is caused by intragenic transcription initiation
- Author
-
B.A. van der Reijden, Joost H.A. Martens, Nilofar Sharifi, Hendrik G. Stunnenberg, Eva M. Janssen-Megens, Joop H. Jansen, Christian M. Zwaan, Saskia M. Bergevoet, Bowon Kim, Mathijs A. Sanders, J Knijnenburg, Anna E. Marneth, Peter J. M. Valk, Maarten Fornerod, A. S. Al Hinai, T C J M Arentsen-Peters, Torsten Haferlach, Jorren Kuster, E C G Stoetman, Marie-Laure Yaspo, Niccolò Tesi, M M van den Heuvel-Eibrink, Koen H.M. Prange, Medical Biochemistry, ACS - Atherosclerosis & ischemic syndromes, Hematology, Clinical Genetics, and Pediatrics
- Subjects
0301 basic medicine ,Transcriptional Activation ,Cancer Research ,Cancer development and immune defence Radboud Institute for Molecular Life Sciences [Radboudumc 2] ,Nerve Tissue Proteins ,Biology ,Translocation, Genetic ,Cell Line ,Epigenesis, Genetic ,Histones ,03 medical and health sciences ,Exon ,Transcription (biology) ,hemic and lymphatic diseases ,Humans ,Protein Interaction Domains and Motifs ,Promoter Regions, Genetic ,Molecular Biology ,Gene ,Regulation of gene expression ,Gene Rearrangement ,Gene Expression Regulation, Leukemic ,Chromosomes, Human, Pair 11 ,Intron ,Myeloid leukemia ,Nuclear Proteins ,Hematology ,Gene rearrangement ,Exons ,Histone-Lysine N-Methyltransferase ,Molecular biology ,Introns ,Leukemia, Myeloid, Acute ,030104 developmental biology ,KMT2A ,Oncology ,biology.protein ,Chromosomes, Human, Pair 16 ,Myeloid-Lymphoid Leukemia Protein - Abstract
Overexpression of the BRE (brain and reproductive organ-expressed) gene defines a distinct pediatric and adult acute myeloid leukemia (AML) subgroup. Here we identify a promoter enriched for active chromatin marks in BRE intron 4 causing strong biallelic expression of a previously unknown C-terminal BRE transcript. This transcript starts with BRE intron 4 sequences spliced to exon 5 and downstream sequences, and if translated might code for an N terminally truncated BRE protein. Remarkably, the new BRE transcript was highly expressed in over 50% of 11q23/KMT2A (lysine methyl transferase 2A)-rearranged and t(8;16)/KAT6A-CREBBP cases, while it was virtually absent from other AML subsets and normal tissues. In gene reporter assays, the leukemia-specific fusion protein KMT2A-MLLT3 transactivated the intragenic BRE promoter. Further epigenome analyses revealed 97 additional intragenic promoter marks frequently bound by KMT2A in AML with C-terminal BRE expression. The corresponding genes may be part of a context-dependent KMT2A-MLLT3-driven oncogenic program, because they were higher expressed in this AML subtype compared with other groups. C-terminal BRE might be an important contributor to this program because in a case with relapsed AML, we observed an ins(11;2) fusing CHORDC1 to BRE at the region where intragenic transcription starts in KMT2A-rearranged and KAT6A-CREBBP AML.Leukemia advance online publication, 24 October 2017; doi:10.1038/leu.2017.280.
- Published
- 2017
- Full Text
- View/download PDF